Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Calcium Channel Blocker Market, by Region, 2019-2029 (USD Billion)
1.2.2. Calcium Channel Blocker Market, by Drug Class, 2019-2029 (USD Billion)
1.2.3. Calcium Channel Blocker Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Calcium Channel Blocker Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Calcium Channel Blocker Market Dynamics
3.1. Calcium Channel Blocker Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increase in Cardiovascular Diseases
3.1.1.2. Rising demand for oral drugs
3.1.2. Market Challenges
3.1.2.1. Lack of skilled professionals
3.1.3. Market Opportunities
3.1.3.1. Increasing demand for retail pharmacies
3.1.3.2. Increased clinical studies and government initiatives
Chapter 4. Global Calcium Channel Blocker Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Calcium Channel Blocker Market, by Drug Class
6.1. Market Snapshot
6.2. Global Calcium Channel Blocker Market by Drug Class, Performance - Potential Analysis
6.3. Global Calcium Channel Blocker Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
6.4. Calcium Channel Blocker Market, Sub Segment Analysis
6.4.1. Dihydropyridine
6.4.2. Benzothizepine
6.4.3. Phenylalkylamine
Chapter 7. Global Calcium Channel Blocker Market, by Distribution Channel
7.1. Market Snapshot
7.2. Global Calcium Channel Blocker Market by Distribution Channel, Performance - Potential Analysis
7.3. Global Calcium Channel Blocker Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
7.4. Calcium Channel Blocker Market, Sub Segment Analysis
7.4.1. Hospitals
7.4.2. Retail Pharmacies
7.4.3. Others
Chapter 8. Global Calcium Channel Blocker Market, Regional Analysis
8.1. Calcium Channel Blocker Market, Regional Market Snapshot
8.2. North America Calcium Channel Blocker Market
8.2.1. U.S. Calcium Channel Blocker Market
8.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Calcium Channel Blocker Market
8.3. Europe Calcium Channel Blocker Market Snapshot
8.3.1. U.K. Calcium Channel Blocker Market
8.3.2. Germany Calcium Channel Blocker Market
8.3.3. France Calcium Channel Blocker Market
8.3.4. Spain Calcium Channel Blocker Market
8.3.5. Italy Calcium Channel Blocker Market
8.3.6. Rest of Europe Calcium Channel Blocker Market
8.4. Asia-Pacific Calcium Channel Blocker Market Snapshot
8.4.1. China Calcium Channel Blocker Market
8.4.2. India Calcium Channel Blocker Market
8.4.3. Japan Calcium Channel Blocker Market
8.4.4. Australia Calcium Channel Blocker Market
8.4.5. South Korea Calcium Channel Blocker Market
8.4.6. Rest of Asia Pacific Calcium Channel Blocker Market
8.5. Latin America Calcium Channel Blocker Market Snapshot
8.5.1. Brazil Calcium Channel Blocker Market
8.5.2. Mexico Calcium Channel Blocker Market
8.6. Rest of The World Calcium Channel Blocker Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Bausch Health Company Inc.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Abbvie Inc
9.2.3. Lupin Pharmaceuticals, Inc
9.2.4. Arbor Pharmaceuticals LLC
9.2.5. Alvogen
9.2.6. Exela Pharma Sciences, LLC
9.2.7. Covis Pharma BV
9.2.8. Novartis AG
9.2.9. GlaxoSmithKline LLC
9.2.10. Pfizer Inc
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption